After posting positive results from a midstage test of its oral immunotherapy AR101 last spring, Aimmune Therapeutics will try out its peanut allergy…

The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam.

Incyte and Bristol-Myers Squibb/Flexus are set to go to war in the courts over claims that a former scientist stole info around an oncology med.

Roche will pay up to $387 million to license certain classes from the more than 100 groups of possibly novel antibiotics Warp Drive is analyzing.

A new CAR-T approach controlled HIV spread and protected T cells from being attacked by HIV in mouse models.

Genomics England and Inivata are partnering on a pilot study to evaluate the use of blood plasma in cancer liquid biopsy.

The series D follows fast after InflaRx established the potential of its anti-human complement factor C5a monoclonal antibody IFX-1 with phase 2 data. 

The FDA has expanded the clearance of NuVasive’s limb-lengthening system to include bone transport.

After decades of research, a gene therapy to correct a specific genetic mutation is on the brink of being approved by the FDA.

The National Institutes of Health (NIH) has enlisted the help of 11 top biopharma companies to bring new cancer immunotherapies to patients faster.